{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:49:54Z","timestamp":1780084194343,"version":"3.54.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Uveitis is the most frequent extra-articular manifestation of juvenile idiopathic arthritis (JIA). Our study is aimed to evaluate the possible difference in arthritis course depending on uveitis presence in patients with JIA, treated with biologics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From our database of patients with JIA treated with biologics, we extracted patients to whom the first agent was administrated with or without MTX. The exclusion criteria included treatment with current systemic corticosteroids, infliximab, rituximab, observation period &amp;lt;3 years, and no missing data. After selection, 175 patients were eligible for analysis. We evaluated clinically significant flare with joint involvement (which required change of biologic or non-biologic DMARD) and time to flare. We compared two groups: (i) patients with uveitis (<jats:italic>n<\/jats:italic> = 32) and (ii) patients without uveitis (<jats:italic>n<\/jats:italic> = 143). For statistical analysis, we used Cox's regression models, the log-Rank test, <jats:italic>x<\/jats:italic><jats:sup>2<\/jats:sup> test, and the Mann\u2013Whitney test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no difference in gender distribution and achievement of arthritis remission between groups. Patients in the non-uveitis group predominantly received etanercept (64.3%). In the uveitis group, the most prescribed biologic agent was adalimumab (71.9%). The presence of uveitis increased the risk of JIA flare, OR = 3.8 (95% CI: 1.7; 8.7), and the cumulative probability of joint flare, RR = 4.5 (95% CI: 1.7; 12.1), <jats:italic>p<\/jats:italic> =.003, after adjustment on methotrexate, RR = 3.1 (1.6; 6.), <jats:italic>p<\/jats:italic> =.0008. In the subgroup of patients treated with adalimumab, the absence of methotrexate increased the cumulative probability of flare [RR = 6.5 (95% CI: 1.4; 31.1), <jats:italic>p<\/jats:italic> = 0.02].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The presence of uveitis proved to be a risk factor in JIA flare. Methotrexate can decrease the cumulative flare probability. Further trials are required.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.849940","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T07:34:38Z","timestamp":1655278478000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Uveitis Is a Risk Factor for Juvenile Idiopathic Arthritis' Significant Flare in Patients Treated With Biologics"],"prefix":"10.3389","volume":"10","author":[{"given":"Mikhail M.","family":"Kostik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina V.","family":"Gaidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubov S.","family":"Sorokina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya S.","family":"Avrusin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana N.","family":"Nikitina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia A.","family":"Isupova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina A.","family":"Chikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri Yu.","family":"Korin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta D.","family":"Orlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila S.","family":"Snegireva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera V.","family":"Masalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita F.","family":"Dubko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga V.","family":"Kalashnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav G.","family":"Chasnyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acr.23871","article-title":"2019 American college of rheumatology\/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis","volume":"71","author":"Angeles-Han","year":"2019","journal-title":"Arthritis Care Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jcjo.2017.01.011","article-title":"Adult patients with uveitis associated with juvenile idiopathic arthritis: a retrospective review","volume":"52","author":"Kolomeyer","year":"2017","journal-title":"Can J Ophthalmol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0164312","DOI":"10.1371\/journal.pone.0164312","article-title":"Impact of juvenile idiopathic arthritis associated uveitis in early adulthood","volume":"11","author":"Haasnoot","year":"2016","journal-title":"PLoS ONE"},{"key":"B5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-015-0018-8","article-title":"Characteristics of a cohort of children with juvenile idiopathic arthritis and JIA-associated uveitis","volume":"13","author":"Angeles-Han","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"108322","DOI":"10.1016\/j.clim.2019.108322","article-title":"Juvenile idiopathic arthritis-associated uveitis","volume":"211","author":"Sen","year":"2020","journal-title":"Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3109\/09273948.2013.791701","article-title":"Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors","volume":"21","author":"Heiligenhaus","year":"2013","journal-title":"Ocul Immunol Inflamm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"SYCAMORE Study Group. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE study group. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3899\/jrheum.171006","article-title":"Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis","volume":"45","author":"Cecchin","year":"2018","journal-title":"J Rheumatol."},{"key":"B11","first-page":"390","article-title":"International league of associations for rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1093\/rheumatology\/keaa733","article-title":"Paediatric Rheumatology International Trials Organisation (PRINTO). A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis","volume":"60","author":"van Straalen","year":"2021","journal-title":"Rheumatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/art.40544","article-title":"Risk factors and biomarkers for the occurrence of uveitis in juvenile idiopathic arthritis: data from the inception cohort of newly diagnosed patients with juvenile idiopathic arthritis study","volume":"70","author":"Tappeiner","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/09273940600977233","article-title":"Extended oligoarthritis and other risk factors for developing JIA-associated uveitis under ILAR classification and its implication for current screening guideline","volume":"14","author":"Sim","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"key":"B16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12969-016-0088-2","article-title":"Juvenile idiopathic arthritis-associated uveitis","volume":"14","author":"Clarke","year":"2016","journal-title":"Pediatr Rheumatol Online J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"461078","DOI":"10.1155\/2014\/461078","article-title":"The role of gender in juvenile idiopathic arthritis-associated uveitis","volume":"2014","author":"Moradi","year":"2014","journal-title":"J Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"740057","DOI":"10.3389\/fphar.2021.740057","article-title":"TNF-\u03b1 in uveitis: from bench to clinic","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/cei.12782","article-title":"The impact of disease activity and tumour necrosis factor-\u03b1 inhibitor therapy on cytokine levels in juvenile idiopathic arthritis","volume":"184","author":"Walters","year":"2016","journal-title":"Clin Exp Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"682327","DOI":"10.3389\/fped.2021.682327","article-title":"Long term experience in patients with JIA-associated uveitis in a large referral center","volume":"9","author":"Marelli","year":"2021","journal-title":"Front Pediatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ophtha.2020.08.024","article-title":"Nordic study group of pediatric rheumatology. Uveitis in juvenile idiopathic arthritis: 18-year outcome in the population-based Nordic cohort study","volume":"128","author":"Rypdal","year":"2021","journal-title":"Ophthalmology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/acr.24483","article-title":"The temporal relationship between juvenile idiopathic arthritis disease activity and uveitis activity","volume":"74","author":"Liebling","year":"2020","journal-title":"Arthritis Care Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3899\/jrheum.191085","article-title":"Enthesitis-related arthritis: prevalence and complications of associated uveitis in children and adolescents from a population-based nationwide study in Germany","volume":"48","author":"Walscheid","year":"2021","journal-title":"J Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e001047","DOI":"10.1136\/rmdopen-2019-001047","article-title":"Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial","volume":"6","author":"Ducourau","year":"2020","journal-title":"RMD Open."},{"key":"B25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1745-6215-15-14","article-title":"SYCAMORE Trial Management Group. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)","volume":"15","author":"Ramanan","year":"2014","journal-title":"Trials"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3899\/jrheum.121180","article-title":"Response of pediatric uveitis to tumor necrosis factor-\u03b1 inhibitors","volume":"40","author":"Lerman","year":"2013","journal-title":"J Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e001208","DOI":"10.1136\/rmdopen-2020-001208","article-title":"Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate","volume":"6","author":"Lovell","year":"2020"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/acr.24044","article-title":"Paediatric rheumatology international trials organisation, and the pediatric rheumatology collaborative study group. Safety and effectiveness of adalimumab in patients with polyarticular course of juvenile idiopathic arthritis: STRIVE registry seven-year interim results","volume":"72","author":"Brunner","year":"2020","journal-title":"Arthritis Care Res"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.849940\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T07:34:44Z","timestamp":1655278484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.849940\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":29,"alternative-id":["10.3389\/fped.2022.849940"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.849940","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"article-number":"849940"}}